Vivo Opportunity Fund Holdings, L.P. → InMed Pharmaceuticals Inc. INM

On May 19, 2026, the Issuer, Indigo Merger Sub Corp., a Delaware corporation and a wholly owned subsidiary of the Issuer (the "First Merger Sub"), Indigo Merger Sub II, LLC, a Delaware limited liability company and a wholly owned subsidiary of the Issuer (the "Second Merger Sub" and, together with First Merger Sub, the "Merger Subs"), and Mentari Therapeutics, Inc., a Delaware corporation ("Mentari"), entered into an Agreement and Plan of Merger and Reorganization (the "Merger Agreement"), pursuant to which, among other matters and subject to the satisfaction or waiver of the conditions set forth in the Merger Agreement, (i) the First Merger Sub will merge with and into Mentari, with Mentari surviving the merger as a wholly owned subsidiary of the Company (the "First Merger"), and (ii) immediately following the First Merger and as part of the same overall transaction as the First Merger, Mentari will merge with and into the Second Merger Sub, with the Second Merger Sub surviving such merger (the "Second Merger" and, together with the First Merger, the "Merger"). Subject to the terms and conditions of the Merger Agreement, at the effective time of the First Merger (the "First Effective Time"), each share of Mentari capital stock outstanding immediately prior to the First Effective Time will be converted into the right to receive a number of the Issuer's common shares (the "Common Shares") equal to the exchange ratio determined under the Merger Agreement (the "Exchange Ratio"). Concurrently with the execution of the Merger Agreement, certain investors, including Vivo Opportunity Fund Holdings, L.P and Vivo Opportunity Cayman Fund, L.P., executed a Securities Purchase Agreement with Mentari, pursuant to which they agreed to purchase, immediately prior to the First Effective Time, shares of Mentari's common stock in the pre-closing financing. The closing of the pre-closing financing is conditioned upon the closing of the Merger. Upon closing of the pre-closing financing, shares of Mentari's common stock issued pursuant to this financing transaction will be converted into Common Shares of the Issuer, in accordance with the Exchange Ratio and the Merger Agreement. The foregoing descriptions of the Merger Agreement and the Mentari Securities Purchase Agreement do not purport to be complete and are qualified in their entirety by the full text of such agreements, which are attached as exhibits to this Schedule 13D and incorporated herein by reference. The Reporting Persons acquired the Common Shares of the Issuer set forth in this Schedule 13D on the open market, starting on May 19, 2026, after the announcement of the Merger Agreement by the Issuer, and ending on June 8, 2026. The Reporting Persons hold the Common Shares for investment purposes.